Vidarikand: Benefits, Evidence, Dosage & Safety

TL;DR

Vidarikand (Pueraria tuberosa), or Indian kudzu, is an Ayurvedic rasayana traditionally used as a rejuvenative tonic. Its only human trial is a small 12-week study in 30 stage-1 hypertensives: 3 g of tuber powder daily lowered systolic pressure by 25 mmHg versus placebo. The result is intriguing but unreplicated: everything else is animal and laboratory data.

(57 words. Sources: Verma et al. 2012, single-blind placebo-controlled trial; IJAAR classical review; PMC review of traditional uses and pharmacology.)

What it is

Vidarikand (also spelled vidarikanda) is the tuber of Pueraria tuberosa (Roxb. ex Willd.) DC., a perennial woody climber of the legume family (Fabaceae) with large tuberous roots, distributed across India up to about 1,200 m elevation and commonly called Indian kudzu (Verma et al., Pak J Biol Sci). The tuber is the medicinal part; its studied constituents include puerarin and related isoflavonoid compounds (PMC review).

Traditional use

Vidarikand is described in all the major Ayurvedic classics and nighantus. Its Ayurvedic properties are given as madhura rasa (sweet taste), shita virya (cooling potency), and guru, snigdha guna (heavy, unctuous qualities), pacifying Vata, Pitta, and Rakta. It is credited with brihani (nourishing), vrushya (aphrodisiac), jivniya (life-promoting), rasayana (rejuvenative), stanya (galactagogue), shukrala (semen-promoting), and balya (strength-promoting) actions, and its formulations are used across conditions including jvara (fever), raktapitta (bleeding disorders), rajayakshma (wasting/consumption), kasa (cough), and klaibya (impotence) (IJAAR classical review). These are traditional claims, not clinical proof: the one human trial is assessed separately below.

What modern research says

Blood pressure

The entire human evidence base for vidarikand is a single trial. In a 12-week, single-blind, placebo-controlled study, 30 patients with stage 1 (primary) hypertension were randomized: 15 received 3 g of P. tuberosa tuber powder daily in two divided doses, and 15 received matched placebo (Verma et al., 2012). By week 12, the vidarikand group showed a fall of 25 mmHg in systolic (p<0.001), 11 mmHg in diastolic (p<0.05), and 16 mmHg in mean blood pressure (p<0.001). Plasma fibrinogen fell significantly (p<0.01), plasma fibrinolytic activity rose (p<0.001), and total antioxidant status improved (p<0.05); the placebo group changed on none of these measures. It was "tolerated well without any untoward side effects."

That is a striking result from a tiny, single-blind trial at one center: it has never been replicated. Treat it as a lead worth following up, not as established fact.

Everything else is preclinical

A 2021 peer-reviewed review catalogues animal and laboratory findings, antidiabetic effects in streptozotocin- and alloxan-induced diabetic rats, anti-stress effects in rats (reduced corticosterone, protection from gastric mucosal damage), and antioxidant activity, but these are rat studies, and the review itself notes that activities such as the antioxidant effects "are yet to be proved in humans" (PMC review). Do not read human efficacy into them.

What the evidence does not support (yet)

Rejuvenation, aphrodisiac effects, galactagogue effects, and anti-TB or anti-diabetic effects in humans: none of these has been tested in a published human trial.

Dosage

The only human regimen is the one from the hypertension trial: 3 g of tuber powder per day in two divided doses for 12 weeks: a research dose, not a personal recommendation (Verma et al., 2012). There is no pharmacopoeial dose cited in the sources reviewed, and no dose has been tested for any other condition. Do not self-dose based on a single small trial.

Safety & contraindications

In the 12-week trial, vidarikand was well tolerated with no reported adverse effects: but that is 15 people over 12 weeks, which proves little about long-term safety (Verma et al., 2012). Longer-term human safety data do not exist. Reasonable cautions: because the single trial found a blood-pressure-lowering effect, anyone on antihypertensive medication should only consider it with a clinician's involvement (additive effects are plausible but untested), and there are no safety data for pregnancy or breastfeeding.

FAQs

What is vidarikand used for in Ayurveda?

It is a classical rasayana (rejuvenative) tonic, traditionally used for strength, vitality, reproductive health, lactation support, and wasting conditions: with sweet taste and cooling potency in Ayurvedic terms (IJAAR classical review). Traditional use is not clinical proof.

Does vidarikand lower blood pressure?

One small 12-week trial in 30 stage-1 hypertensives found 3 g/day of tuber powder lowered systolic pressure by 25 mmHg versus placebo (Verma et al., 2012). The trial was small, single-blind, and unreplicated: promising, not proven.

Is vidarikand the same as kudzu?

It is called Indian kudzu, but it is Pueraria tuberosa, a distinct species from the kudzu (P. lobata) used in Chinese medicine: results from one species do not transfer to the other.

How much vidarikand was used in the study?

3 g of tuber powder per day, split into two doses, for 12 weeks (Verma et al., 2012). That is a research regimen from one small trial, not a recommended dose.

Is vidarikand safe?

It was well tolerated in the single 12-week trial, but longer-term human safety data do not exist. People on blood-pressure medication, and anyone pregnant or breastfeeding, should involve a clinician rather than self-directing use.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.